TRIM5␣ is a tripartite motif (TRIM) protein that consists of RING, B-box 2, coiled-coil, and B30.2(SPRY) domains. The TRIM5␣ rh protein from rhesus monkeys recognizes the human immunodeficiency virus type 1 (HIV-1) capsid as it enters the host cell and blocks virus infection prior to reverse transcription. HIV-1-restricting ability can be eliminated by disruption of the B-box 2 domain. Changes in the TRIM5␣ rh B-box 2 domain have been associated with alterations in TRIM5␣ rh turnover, the formation of cytoplasmic bodies and higher-order oligomerization. We present here the nuclear magnetic resonance structure of the TRIM5 B-box 2 domain and identify an unusual hydrophobic patch (cluster 1) on the domain surface. Alteration of cluster 1 or the flanking arginine 121 resulted in various degrees of inactivation of HIV-1 restriction, in some cases depending on compensatory changes in other nearby charged residues. For this panel of TRIM5␣ rh B-box 2 mutants, inhibition of HIV-1 infection was strongly correlated with higher-order self-association and binding affinity for capsid complexes but not with TRIM5␣ rh half-life or the formation of cytoplasmic bodies. Thus, promoting cooperative TRIM5␣ rh interactions with the HIV-1 capsid represents a major mechanism whereby the B-box 2 domain potentiates HIV-1 restriction.
TRIM5␣ is a tripartite motif (TRIM) protein that consists of RING, B-box 2, coiled-coil, and B30.2(SPRY)
domains. The TRIM5␣ rh protein from rhesus monkeys recognizes the human immunodeficiency virus type 1 (HIV-1) capsid as it enters the host cell and blocks virus infection prior to reverse transcription. HIV-1-restricting ability can be eliminated by disruption of the B-box 2 domain. Changes in the TRIM5␣ rh B-box 2 domain have been associated with alterations in TRIM5␣ rh turnover, the formation of cytoplasmic bodies and higher-order oligomerization. We present here the nuclear magnetic resonance structure of the TRIM5 B-box 2 domain and identify an unusual hydrophobic patch (cluster 1) on the domain surface. Alteration of cluster 1 or the flanking arginine 121 resulted in various degrees of inactivation of HIV-1 restriction, in some cases depending on compensatory changes in other nearby charged residues. For this panel of TRIM5␣ rh B-box 2 mutants, inhibition of HIV-1 infection was strongly correlated with higher-order self-association and binding affinity for capsid complexes but not with TRIM5␣ rh half-life or the formation of cytoplasmic bodies. Thus, promoting cooperative TRIM5␣ rh interactions with the HIV-1 capsid represents a major mechanism whereby the B-box 2 domain potentiates HIV-1 restriction.
Mammalian proteins that can dominantly block retroviral infection by interfering with the early phase of viral replication have been identified (1a, 47, 50) . One member of the tripartite motif (TRIM) family of proteins, TRIM5␣, mediates species-specific restriction of particular retroviruses from diverse retrovirus subfamilies. For example, TRIM5␣ from rhesus macaques (TRIM5␣ rh ) blocks infection of human immunodeficiency virus type 1 (HIV-1) soon after viral entry but prior to reverse transcription (22, 50) . Although human TRIM5␣ (TRIM5␣ hu ) only weakly inhibits HIV-1 infection, this protein potently inhibits infection by N-tropic murine leukemia virus (N-MLV) (16, 39, 42, 47, 57) . Some species of Old World and New World monkeys encode TRIMCyp instead of TRIM5␣; TRIMCyp is a fusion of TRIM5 and cyclophilin A and restricts some retroviruses, including HIV-1 (4, 16, 38, 39, 42, 47, (55) (56) (57) .
TRIM5␣ is composed of RING, B-box 2, and coiled-coil domains typical of TRIM proteins and a carboxy-terminal B30.2(SPRY) domain. The RING domain is not absolutely required for, but contributes to the potency of, retroviral restriction; the RING domain plays an important role in the rapid degradation of TRIM5␣ (11) . Some changes in the B-box 2 domain exert dramatic effects on retrovirus-restricting ability (10, 19, 40) . The coiled-coil domain allows oligomerization of TRIM5␣ (20, 36) , which recently has been shown to be a dimer (16, 39, 42, 47, 57) . Dimerization contributes to the avidity of TRIM5␣ for the HIV-1 capsid (51). The B30.2(SPRY) domain, which mediates capsid recognition, dictates the viral specificity of restriction (46, 52, 58) . Sequence divergence within variable regions of the B30.2(SPRY) domain accounts for species-specific differences in the potency of restriction (46, 52, 58) .
Structural and functional similarities exist between the RING and B-box domains of TRIM proteins. Both domains bind two zinc atoms tetrahedrally in a cross-brace conformation (3, 17, 34, 35) . Furthermore, both domains have been shown to be involved in protein-protein interactions. In non-TRIM proteins, RING domains play the role of molecular scaffolds, allowing formation of supramolecular complexes by self-association, which in some cases improves enzymatic activity (2, 23, 24, 43) . Interestingly, RING-RING interactions have been reported to be functionally important for genomic stability, as in the heterodimer formed by the RING domain of BRCA1 with the RING domain of BARD-1 (5) .
The B-box domain is found in extremely diverse proteins; in TRIM proteins, the B-box domain is present in one or two copies (44, 54) . B-box domains have been implicated in protein-protein interactions (32, 53) and have been shown to play a role in protein localization, growth control, differentiation, and transcriptional regulation (54) . The B-box domain usually adopts a ␤␤␣ conformation reminiscent of the RING domain.
Some TRIM proteins, such as MID1 (TRIM18), contain two B-box domains in tandem. Structural studies demonstrated that the tandem B-boxes of MID1 pack against each other (53) . The contact interface between the two B-boxes is made by the short ␤-strands of each B-box domain. Mutations affecting either one of these B-box domains occur in patients with Opitz G/BBB syndrome, a severe developmental disorder (48) . Recent structural studies of the B-box 2 domain of MuRF1 (TRIM63) identified a dimer interface that consists of a hydrophobic surface and polar residues (46, 52, 58) . These findings suggest that B-box-B-box interactions may have functional significance.
Using models based on the B-box 1 or B-box 2 structures of other proteins, mutagenesis of putative surface-exposed residues of the TRIM5␣ rh B-box 2 domain has been conducted (10, 19, 40) . These studies have revealed several functions dependent upon the intact TRIM5␣ rh B-box 2 domain. First, the wild-type TRIM5␣ proteins of humans and rhesus monkeys are turned over rapidly, with a half-life of less than 1 h (11). Alteration of specific basic residues in the TRIM5␣ rh B-box 2 domain results in much more stable proteins; because some of these mutants retain antiretroviral activity, rapid turnover of TRIM5␣ appears not to be essential to retrovirusrestricting ability (10) .
Second, a change in the B-box 2 domain of TRIM5␣ can affect the higher-order self-association of TRIM5␣ dimers (32) . This self-association contributes to the ability of TRIM5␣ to bind the retroviral capsid, perhaps by increasing avidity (32) . The contribution of the B-box 2 domain to antiretroviral activity is particularly important when the interactions of the B30.2(SPRY) domain with the viral capsid are weak (31, 32) .
Like many TRIM proteins (44), TRIM5␣ rh forms aggregates called cytoplasmic bodies when overexpressed (11) . A third phenotype associated with TRIM5␣ B-box 2 changes is a decrease in the propensity of the protein to coalesce into cytoplasmic bodies; this phenotype is particularly striking, because many TRIM5␣ B-box 2 mutants are expressed at higher steady-state levels than the wild-type protein (10) . Although cytoplasmic bodies per se are not necessary for TRIM5␣-mediated retroviral restriction (46, 52, 58) , the relationship between higher-order TRIM5␣ self-association, which contributes to capsid binding (32) , and the tendency to form cytoplasmic aggregates is not clear.
Lastly, some TRIM5␣ B-box 2 mutants apparently lose the ability to block retrovirus infection out of proportion to any measured reductions in capsid binding (10, 32) . This observation hints that the B-box 2 domain may mediate functions beyond higher-order self-association and capsid binding. Presumably, such functions could contribute mechanistically to the process whereby TRIM5␣ disrupts the early events in retrovirus infection following the recognition of the capsid after it enters the cytosol. Studies following the fate of the HIV-1 capsid in the cytosol of infected cells have correlated restriction of infection with a decrease in the amount of cytosolic particulate capsids (51) . Similar changes have been observed in the amount of cytosolic particulate capsids during infection of HIV-1 and N-MLV in the presence of the restriction factors TRIMCyp and TRIM5␣ hu , respectively (10, 41) . In contrast to the wild-type TRIM5␣ hu protein, a TRIM5␣ hu B-box 2 mutant defective for N-MLV restriction did not cause a reduction in the amount of particulate capsid in the cytosol (46, 52, 58) . Thus, B-box 2 functions may contribute to the accelerated uncoating of the retroviral capsid associated with TRIM5␣ restriction.
We present here a nuclear magnetic resonance (NMR) structure of the TRIM5 B-box 2 domain and demonstrate a weak tendency of the purified B-box 2 domains to self-associate. Alteration of the unusually hydrophobic surface or flanking charged amino acid residues of the TRIM5␣ rh B-box 2 domain revealed structures important for rapid turnover, higher-order self-association, cytoplasmic body formation, capsid binding, and retrovirus restriction. To understand which B-box 2 functions contribute to retroviral restriction, the relationships among these TRIM5␣ properties were investigated. Both higher-order self-association and binding to the viral capsid strongly correlated with inhibition of HIV-1 infection, implying that the B-box 2 domain potentiates retroviral restriction by promoting cooperative TRIM5␣ interactions with the capsid.
MATERIALS AND METHODS
Sample preparation of the TRIM5 B-box 2 domain. The DNA fragment encoding the B-box 2 of human TRIM5␣ (amino acid residues S86 to T131 [Swiss-Prot Q9C035]) was amplified via PCR from the Research Association for Biotechnology Clone FLJ14687 and was cloned into the plasmid vector pCR2.1 (Invitrogen, Carlsbad, CA) as a fusion with an N-terminal His tag and a tobacco etch virus protease cleavage site. The 13 C-and 15 N-labeled protein was synthesized by a cell-free protein expression system (25) . Purification was performed by a standard procedure (29) . For structure determination, a single 1.13 mM uniformly 13 C-and 15 N-labeled sample was prepared in 20 mM Tris-HCl buffer (pH 7.0), 100 mM NaCl, 1 mM dithiothreitol (DTT), 0.02% NaN 3 , 0.05 mM ZnCl 2 , and 1 mM iminodiacetic acid, with the addition of D 2 O to 10% (vol/vol). The engineered protein sample used for the NMR measurements was comprised of 46 amino acid residues from human TRIM5 spanning the B-box 2 domain (residues 86 to 131 of TRIM5␣ hu ); the first seven and last six residues of the protein consist of tags. The residues of this engineered protein are referred to as 79 to 137, so that the numbers of the B-box 2 residues correspond to those of human TRIM5.
NMR spectroscopy, structure determination, and analysis. All of the NMR spectra were recorded at 20°C on Varian INOVA 600, 800, and 900 spectrometers equipped with pulsed-field gradient triple-resonance probes. Sequence-specific resonance assignments were made using the standard triple-resonance techniques. The backbone assignment was achieved by the combined analysis of HNCO, (HCA)CO (CA)NH, HN(CO)CA, HNCACB, and CBCA(CO)NH spectra. The side chain resonances were identified by the combinational use of HBHANH, HBHA (CO)NH, (H)CC(CO)NH, (H)CCH-TOCSY, HCCH-TOCSY, and two-dimensional The NMRpipe software package (7) and the program KUJIRA (26) , created on the basis of NMRView (21), was used for optimal visualization and spectral analysis. Automated NOE cross-peak assignments (18) and structure calculations with the torsion angle dynamics were performed using the software package CYANA2.0.17 (15) .
Dihedral angle restraints were derived using the program TALOS (6) . A total of 100 conformers were calculated independently. The 20 conformers with the lowest final CYANA target function values were finally selected. The structures were validated by using PROCHECK-NMR (28) . The program MOLMOL (27) was used to analyze the resulting 20 conformers and to prepare drawings of the structures, unless noted otherwise in the legends.
The selected 20 conformers have been deposited in the Protein Data Bank (PDB entry 2YRG).
Dynamic light-scattering experiment. The data were measured at 4°C by using a DynaPro light scattering system (Protein Solutions, Lakewood, NJ) and a microsampler, with a protein concentration of 2.2 mg/ml in 20 mM Tris-HCl buffer (pH 7.0) containing 100 mM NaCl and 1 mM iminodiacetic acid. Dynamics Version 5.0 software (Protein Solutions) was used in the data collection and analysis.
Analytical ultracentrifugation. Sedimentation equilibrium experiments were performed on a Beckman Optima XL-I centrifuge, in an eight-position An-50Ti rotor with equilibrium six-channel centerpieces and quartz windows. Experiments were carried out at 4°C with the B-box 2 domain protein in solution at concentrations of 1.2, 0.8, 0.4, and 0.2 mg/ml and at rotor speeds of 20,000, 22,000, and 24,000 rpm for the dimeric molecular weight range and 30,000, 31,000, and 32,000 rpm for the monomeric molecular weight range. The data were corrected after 12, 14, and 16 h at each speed. Protein concentration profiles were monitored by the absorbance at 280 nm. To generate the baseline, the samples were then completely sedimented at 40,000 rpm for 6 h at 4°C. For the calculation of the molecular weight, corrected datasets were analyzed in the self-association model with a partial specific volume of 0.705 ml/g and a solvent density of 1.003 g/ml, using the Beckman XL-A/XL-I data analysis software (version 6.03).
Creation of cells stably expressing TRIM5␣ variants. Retroviral vectors encoding wild-type or mutant rhesus monkey TRIM5␣ rh proteins were created using the pLPCX vector. The TRIM5␣ rh proteins contained an influenza hemagglutinin (HA) epitope tag at the C terminus or FLAG epitope tags at the N terminus. Recombinant viruses were produced in 293T cells by cotransfecting the pLPCX plasmids with the pVPack-GP and pVPack-VSV-G packaging plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the vesicular stomatitis virus G envelope glycoprotein, which allows efficient entry into a wide range of vertebrate cells (59) . Cf2Th canine thymocytes were transduced and selected in 5 g of puromycin (Sigma)/ml.
Infection with viruses expressing GFP. Recombinant HIV-1 and N-MLV expressing green fluorescent protein (GFP) were prepared as described previously (12, 50) . All recombinant viruses were pseudotyped with the vesicular stomatitis virus G glycoprotein. For infections, 3 ϫ 10 4 Cf2Th cells seeded in 24-well plates were incubated at 37°C with virus for 24 h. Cells were washed and returned to culture for 48 h and then subjected to fluorescence-activated cell sorting (FACS) analysis with a FACScan (Becton Dickinson). HIV-1 and N-MLV viral stocks were titrated by serial dilution on Cf2Th cells to determine the concentration of infectious viruses.
Protein analysis. Cellular proteins were extracted with radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris [pH 7.4], 100 mM NaCl, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1% NP-40, 2 mg of aprotinin/ ml, 2 mg of leupeptin/ml, 1 mg of pepstatin A/ml, 100 mg of phenylmethylsulfonyl fluoride/ml). The cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE; 10% acrylamide), followed by blotting onto nitrocellulose membranes (Amersham Pharmacia Biotech). Detection of protein by Western blotting utilized monoclonal antibodies directed against the hemagglutinin (HA) epitope tags (Roche) and FLAG epitope tags (Sigma) and monoclonal antibodies to ␤-actin (Sigma). All monoclonal antibodies were directly conjugated to horseradish peroxidase. Proteins were detected by enhanced chemiluminescence (NEN Life Sciences Products) using the FluorChem FC2 detection system (Alpha Innotech). Signals were acquired as an image file (TIFF) and quantified by using QuantityOne software (Bio-Rad Laboratories).
TRIM5␣ dimerization. Approximately 10 7 293T cells transfected with 5 g of plasmids expressing TRIM5␣ rh variants were lysed in NP-40 lysis buffer (0.5% NP-40 in phosphate-buffered saline [PBS] ) and cross-linked with different concentrations (0to 10 mM) of ethylene glycolbis-succinimidylsuccinate (EGS) for 30 min as previously described (10) . The cross-linking reaction was stopped by adding 10 l of 1 M Tris-HCl. After cross-linking, the samples were resuspended in 2ϫ sample buffer, followed by incubation at 37°C for 30 min. Samples were analyzed by SDS-PAGE and Western blotting with an anti-HA antibody (Roche).
Higher-order self-association of TRIM5␣. Human 293T cells were independently transfected with plasmids encoding FLAG-tagged and HA-tagged mutant and wild-type TRIM5␣ rh proteins. After 48 h, the cells expressing each TRIM5␣ rh variant were lysed in 1 ml of whole-cell extract buffer (50 mM Tris [pH 8.0], 280 mM NaCl, 0.5% IGEPAL-10% glycerol, 1 mM DTT, protease inhibitor cocktail [Roche]). Lysates were centrifuged at 14,000 rpm for 1 h at 4°C. Post-spin lysates were then precleared using protein A-agarose (Sigma) for 1 h at 4°C; a small aliquot of each of these lysates was stored as an INPUT sample. Precleared lysates containing the differently tagged proteins were mixed in a 1/1 ratio and incubated with anti-FLAG-agarose beads (Sigma) for 2 h at 4°C to precipitate the FLAG-tagged proteins. Beads containing the immunoprecipitate were washed four times in whole-cell extract buffer. Subsequently, immune complexes were eluted using 200 g of FLAG tripeptide/ml in whole-cell extract buffer. The eluted samples were separated by SDS-PAGE and analyzed by Western blotting using anti-HA or anti-FLAG antibodies conjugated to horseradish peroxidase. S protein-labeling mix; Perkin-Elmer)/ml in Dulbecco modified Eagle medium lacking methionine and cysteine and supplemented with 5% dialyzed fetal bovine serum. The cells were then chased for different time intervals in Dulbecco modified Eagle medium containing an excess of unlabeled methionine and cysteine. Cells were subsequently lysed in a modified RIPA buffer (140 mM NaCl, 8 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , 1% NP-40, 0.25% SDS). Samples were subsequently immunoprecipitated with anti-HA antibody-Sepharose beads for 16 h at 4°C. After two washes with modified RIPA buffer, samples were separated by SDS-PAGE (Invitrogen) and analyzed by autoradiography and PhosphorImager (Molecular Dynamics).
Localization of wild-type and mutant TRIM5␣ proteins. The localization of TRIM5␣ rh and variants was investigated as previously described (8) . Briefly, cells were grown overnight on 12-mm-diameter coverslips and fixed in 3.9% paraformaldehyde (Sigma) in PBS (Cellgro) for 30 min. Cells were washed in PBS, incubated in 0.1 M glycine (Sigma) for 10 min, washed in PBS, and permeabilized with 0.05% saponin (Sigma) for 30 min. Samples were blocked with 10% donkey serum (Dako, Carpinteria, CA) for 30 min and incubated for 1 h with antibodies. The anti-HA fluorescein isothiocyanate-conjugated 3F10 antibody (Roche) was used to stain HA-tagged proteins. Subsequently, samples were mounted for fluorescence microscopy by using the ProLong Antifade kit (Molecular Probes, Eugene, OR). Images were obtained with a Bio-Rad Radiance 2000 laser scanning confocal microscope with Nikon 60ϫ N.A.1.4 optics.
HIV-1 CA-NC expression and purification. The HIV-1 CA-NC protein was expressed, purified, and assembled as previously described (13, 14) . The pET11a expression vector (Novagen) expressing the CA-NC protein of HIV-1 was used to transform BL-21(DE3) E. coli. CA-NC expression was induced with 1 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) when the culture reached an optical density of 0.6 at 600 nm. After 4 h of induction, the cells were harvested and resuspended in 20 mM Tris-HCl (pH 7.5), 1 M ZnCl 2 , 10 mM 2-mercaptoethanol, and protease inhibitors (Roche). Lysis was performed by sonication, and debris was pelleted for 30 min at 35,000 ϫ g. Nucleic acids were stripped from the solution by using 0.11 equivalents of 2 M (NH 4 ) 2 SO 4 and the same volume of 10% polyethylenimine. Nucleic acids were removed by stirring and centrifugation at 29,500 ϫ g for 15 min. The protein was recovered by addition of 0.35 equivalents of saturated (NH 4 ) 2 SO 4 . The protein was centrifuged at 9,820 ϫ g for 15 min and resuspended in 100 mM NaCl, 20 mM Tris-HCl (pH 7.5), 1 M ZnCl 2 , and 10 mM 2-mercaptoethanol. The CA-NC protein was dialyzed against 50 mM NaCl, 20 mM Tris-HCl (pH 7.5), 1 M ZnCl 2 , and 10 mM 2-mercaptoethanol, and stored at Ϫ80°C.
In vitro assembly of CA-NC complexes. HIV-1 CA-NC particles were assembled in vitro by diluting the CA-NC protein to a concentration of 0.3 mM in 50 mM Tris-HCl (pH 8.0), 0.5 M NaCl, and 2 mg of DNA oligo-(TG) 50 /ml. The mixture was incubated at 4°C overnight and centrifuged at 8,600 ϫ g for 5 min. The pellet was resuspended in assembly buffer (50 mM Tris-HCl [pH 8.0], 0.5 M NaCl) at a final protein concentration of 0.15 mM (13, 14) and stored at 4°C until needed.
Binding of TRIM5␣ rh variants to HIV-1 capsid complexes. 293T cells were transfected with plasmids expressing wild-type or mutant TRIM5␣ rh proteins. At 48 h after transfection, cell lysates were prepared as follows: previously washed cells were resuspended in hypotonic lysis buffer (10 mM Tris [pH 7.4], 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT). The cell suspension was frozen, thawed, and incubated on ice for 10 min. Afterward, the lysate was centrifuged at full speed in a refrigerated Eppendorf microcentrifuge (ϳ14,000 ϫ g) for 5 min. The supernatant was supplemented with 1/10 volume of 10ϫ PBS and then used in the binding assay. In some cases, samples containing the TRIM5␣ rh variants were diluted with extracts prepared in parallel from untransfected cells. To test binding, 5 l of CA-NC particles assembled in vitro were incubated with 200 l of cell lysate at room temperature for 1 h. A fraction of this mixture was stored (input). The mixture was spun through a 70% sucrose cushion (70% sucrose, 1ϫ PBS, and 0.5 mM DTT) at 100,000 ϫ g in an SW55 rotor (Beckman) for 1 h at 4°C. After centrifugation, the supernatant was carefully removed and the pellet was resuspended in 1ϫ SDS-PAGE loading buffer (pellet). The level of TRIM5␣ rh proteins was determined by Western blotting with an anti-HA antibody, as described above. The level of HIV-1 CA-NC protein in the pellet was assessed by Western blotting with an anti-p24 CA antibody.
Quantitative real-time PCR. Cf2Th cells expressing wild-type and mutant TRIM5␣ rh proteins were challenged with HIV-1 at a multiplicity of infection of 0.2. Viruses were pretreated with DNase to prevent contamination from carryover plasmid DNA. An infection using a virus that was heat-inactivated (60°C for 30 min) was performed as a control for carryover plasmid DNA in the PCR.
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After 6 h, the cells were lysed and DNA was extracted by using a Qiagen blood tissue DNA extraction kit. PCRs were prepared by using the QuantiTect probe PCR kit. Each sample contained 100 ng of total cellular DNA. PCR was carried out using two primers that amplify a 263-bp fragment of GFP: GFP-fwd, 5Ј-GAC GTA AAC GGC CAC AAG-3Ј; GFP-rev, 5Ј-GGT CTT GTA GTT GCC GTC GT-3Ј; and GFP-Probe, 5Ј-56-FAM-CCT ACG GCA AGC TGA CCC TGA-36-TAMRA-3Ј. A calibration curve was prepared using an HIV-1-GFP plasmid.
RESULTS
Solution structure of the TRIM5 B-box 2 domain. A fragment (residues 86 to 131) of human TRIM5 that encompasses the B-box 2 domain was expressed and labeled in a cell-free system. The solution structure of the monomeric protein was determined by using multidimensional NMR spectroscopy (PDB entry 2YRG). The 1 H-15 N and 1 H-13 C HSQC spectra were broad for the size of the protein, but all of the resonances were assigned except for the amide proton of Q121. The solution structures were well defined from residues 93 to 131 (Fig. 1) . The root mean square deviations (RMSDs) from the mean structure were 0.25 Ϯ 0.07 Å for backbone atoms and 0.83 Ϯ 0.10 Å for heavy atoms in the defined region of the domain. The structural statistics are summarized in Table 1 . Like most B-box domains (34, 35) , the B-box 2 domain from TRIM5 adopts a ␤␤␣ RING-like fold, which is maintained by two zinc ions and CHCDC2H2-type zinc coordination. There is also an additional very short ␤-strand just before the helix.
A noteworthy feature of the TRIM5␣ B-box 2 domain is that the majority of hydrophobic residues are solvent exposed and clustered, forming two hydrophobic patches on the domain surface. These hydrophobic surface patches are conserved in the B-box 2 domains of TRIM5␣ proteins from different species; for example, the human and rhesus monkey B-box 2 domains differ in only one amino acid residue, which does not reside within either hydrophobic patch (Fig. 2) . One of the hydrophobic patches (cluster 1) is located on the outer surface of the helix and the first ␤-strand and is formed in human TRIM5␣ by residues L103, L104, W115, and L116. The cluster 1 patch is surrounded by the negatively charged residues E118 and E100 and positively charged residues R119 and K101. The second hydrophobic patch (cluster 2) is formed in human TRIM5␣ by L102, V112, F105, and F129.
Concentration dependence of NMR signals. The residues on the human TRIM5 B-box 2 protein exhibited broadened signals in the 1 H-15 N HSQC spectrum; this contrasts with previous observations with other B-box 2 domains, which usually give sharp signals because of their compact size and stable fold (34) . To investigate the basis of the observed broadening, the concentration dependence of the 1H-1D and 1 H-15 N HSQC spectra was measured (Fig. 3A) . As the protein concentration decreased, the peaks of the amide protons from K101, L116, and W115 and side chain CH protons from L116 were shifted; the broadened peaks of the amide protons from L104 and E118, and the imino proton from the W115 indole ring, were sharpened or appeared. These results indicate that the B-box 2 domains associated via the cluster 1 region in the millimolar range of concentration and dissociated at lower concentrations (Fig. 3B) . We also observed additional chemical shift perturbations (CSPs) in the very low concentration range Ͻ100 M) involving the very narrow region near E108 and H127; this phenomenon may result from the zinc-mediated B-box 2 association at H127 (see below).
Size and affinity of the associated state of the B-box 2 domain. To estimate the oligomeric state of the associated B-box 2 domain in solution, we performed a high-speed sedimentation equilibrium study by analytical ultracentrifugation (Fig.  3C) . The radial distributions at 20,000, 22,000, and 24,000 rpm with a B-box 2 domain concentration of 1.2 mg/ml (ϳ180 M) fitted to a molecular mass of 1.05 ϫ 10 4 Da, which corresponds to 1.57 molecules of the B-box 2 domain. This implies that the B-box 2 domain exists between monomeric and dimeric forms in solution at this concentration. In addition, dynamic light scattering experiments revealed that the B-box 2 domain in solution had a monomodal profile with a narrow peak corresponding to particles with an average hydrodynamic diameter of 3.3 nm and an estimated molecular mass of 11 kDa (data not shown). Although it is difficult to calculate an exact molecular mass by dynamic light scattering, this result is consistent with the TRIM5 B-box 2 domain existing in solution at an average size between those of monomers and dimers. The partial dimer content of TRIM5 B-box 2 solutions may reflect a zinc-mediated self-association of the B-box 2 domain, because we detected a chemical shift change specifically in H127 in the low protein concentration range (Ͻ100 M); in contrast, we did not observe any additional chemical shift changes in other residues in the concentration range from 10 to 660 M (data not shown). We also found that reducing the amount of the weak chelator iminodiacetic acid in the buffer resulted in a much higher average molecular mass in the sedimentation equilibrium measurement and reduced solubility of the B-box 2 protein (data not shown). These results support the interpretation that most of the dimer estimated from the sedimentation equilibrium data resulted from zinc-mediated association. Collectively, the results suggest two types of B-box association, a zinc-mediated association and a direct association involving the region from W115 to E118. The zinc-medi- ated association appears to exhibit a higher affinity but affects the HSQC spectra less. The direct association has a lower affinity but causes major concentration-dependent shifts of NMR peaks that reflected the dynamic equilibrium between zinc-mediated associates.
Since the zinc-mediated association did not cause CSPs except for H127, the CSP data in the other areas of the domain could be fitted independently. The equilibrium dissociation constant (K D ) was calculated to be 9.33 Ϯ 5.40 mM using gnuplot in the dimer model by the analysis of chemical shift changes of the W115 amide proton in the concentration-dependent two-dimensional 1 H-15 N HSQC spectra (Fig. 3D) . The fitting error was very large because of the low affinity and limited solubility of the protein. We estimated that only ca. 10% of the protein contributed to dimerization even at the highest concentration (0.66 mM). This explains the small observed chemical shift changes, even though the indole ring of W115 is apparently included in the binding interface. The small chemical shift changes of the backbone amide protons also suggest that the association does not involve a change of the protein fold and is stabilized by inter-side chain interactions.
Mutagenic analysis of the TRIM5␣ rh B-box 2 surface. To investigate the functional implications of the TRIM5 B-box structure, we modified specific amino acid residues of TRIM5␣ rh . We chose the TRIM5␣ rh protein because it potently restricts HIV-1 infection (50), allowing quantitation of phenotypes over a wide dynamic range. Moreover, most of the assays to evaluate TRIM5␣ phenotypes have been developed using the rhesus monkey protein as a prototype (11, 32, 36, 50, 51) . Because the TRIM5␣ rh and TRIM5␣ hu B-box 2 primary amino acid sequences differ by only one residue (see the alignment in Fig. 2A ), structure-function relationships are expected to be similar between these two domains. Amino acid residues predicted to be surface accessible on the TRIM5␣ rh B-box 2 domain, including those predicted to reside in clusters 1 and 2, were altered (Fig.  2B) . Particular attention was paid to the charged residues surrounding cluster 1, with various combinations of charge substitutions being introduced into this region. The wild-type and mutant TRIM5␣ rh proteins were expressed stably in Cf2Th canine thymocytes, which do not express a TRIM5 ortholog (45) . All of the TRIM5␣ rh mutants studied were expressed at least as well as the wild-type TRIM5␣ rh protein (see Fig. S1 in the supplemental material). The steady-state levels of expression of several of the B-box 2 mutants were greater than that of wild-type TRIM5␣ rh , which has a half-life of ϳ48 min (see Fig. S2 in the supplemental material). Indeed, prolonged half-lives, relative to that of the wild-type TRIM5␣ rh , were associated with many of the TRIM5␣ mutants (Table 2 ). This result is consistent with previous studies that implicated the TRIM5␣ B-box 2 domain in the regulation of TRIM5␣ turnover (10, 11) . All of the TRIM5␣ mutants tested formed dimers detected by EGS cross-linking (see Fig. S3 in the supplemental material and Table 2 ). This result is consistent with previous studies indicating that the TRIM5␣ B-box 2 domain can be deleted without disrupting dimerization (10) .
Retroviral restriction by TRIM5␣ rh B-box 2 mutants. To examine the ability of the TRIM5␣ rh B-box 2 mutants to inhibit retroviral infection, Cf2Th cells expressing these mutants were challenged with recombinant HIV-1 expressing GFP. The TRIM5␣ rh mutants exhibited a range of HIV-1-restricting abilities (Fig. 4) , and are rank-ordered in Table 2 according to restriction potency. Substitution of an acidic residue for arginine 121 (R121E and R121D) completely eliminated the ability of TRIM5␣ rh to inhibit HIV-1 infection, as has been previously seen (10, 32) . Of note, some changes in the glutamic acid residues at 102 and 120, which flank the hydrophobic patch in the cluster 1 region, restored various degrees of HIV-1-restricting activity to the R121D or R121E mutants (Table  2) . For TRIM5␣ rh mutants with an acidic residue at position 121, an arginine substitution for glutamic acid 120 resulted in the best improvement in HIV-1 restriction; lysine and aspartic acid substitutions at residue 120 were less effective. An arginine substitution for E102 was as effective as an arginine substitution for E120 in restoring HIV-1-restricting activity to TRIM5␣ rh variants with the R121E change. Thus, while the presence of three negatively charged residues at positions 102, 120, and 121 was associated with only a low level of TRIM5␣ rh function, arginine substitutions at position 102 or 120 could partially compensate for the presence of an acidic residue at position 121.
The TRIM5␣ rh mutants that retained the wild-type arginine or a lysine residue at position 121 exhibited HIV-1-restricting ability, regardless of the particular amino acid at residue 120. However, the wild-type glutamic acid and aspartic acid residues at position 120 generally allowed the most potent HIV-1 restriction in this case. The alteration of glutamic acid 102 to arginine resulted in only a slight decrease in the potency of HIV-1 restriction when the wild-type arginine 121 was retained on TRIM5␣ rh . These results indicate that the nature of the Of the hydrophobic B-box 2 residues that were altered, changes in W117 and L118, in the cluster 1 hydrophobic patch, exerted the greatest impact on HIV-1-restricting activity. Thus, the TRIM5␣ rh B-box 2 residues important for HIV-1 restriction (arginine 121, leucine 118, and tryptophan 117) occupy a localized area on the domain surface.
The TRIM5␣ rh B-box 2 mutants exhibited a range of HIV-1-restricting activities. The ability of the mutants to restrict N-MLV infection was examined. The wild-type TRIM5␣ rh protein exhibited a modest level of restriction against N-MLV (Table 2) . Whereas a few of the B-box 2 mutants that exhibited wild-type anti-HIV-1 activity retained the ability to inhibit N-MLV weakly, most of the mutants were devoid of detectable N-MLV-restricting ability. Thus, several of the mutants, in- a Restriction was measured by infecting cells expressing the indicated TRIM5␣ rh variants with HIV-1 and N-MLV expressing the GFP protein. After 48 h, the percentage of GFP-positive cells (infected cells) was determined by flow cytometry. For HIV-1: ϩϩϩϩ, 100% restriction; ϩϩϩ, ϳ75% restriction; ϩϩ, ϳ50% restriction; ϩ, ϳ25% restriction; and Ϫ, Ͻ25% or no restriction. For N-MLV: ϩϩ, ϳ50% restriction; ϩ, ϳ25% restriction; and Ϫ, Ͻ25% restriction. Experiments were performed at least three times, and typical results are shown.
b HIV-1 reverse transcription was measured by real-time PCR 6 h after infection as described in Materials and Methods. The number represents the percentage of late reverse transcripts observed in cells expressing the indicated TRIM5␣ rh variant relative to the level of late reverse transcripts in control HIV-1-infected cells transduced with the empty LPCX vector. Experiments were performed at least two times.
c Dimerization of TRIM5␣ rh variants was measured by the use of the cross-linker EGS as described in Materials and Methods. d Each TRIM5␣ rh variant was assayed for higher-order association with wild-type TRIM5␣ rh (association with wild type) or with itself (self-association), as described in Materials and Methods. In the case of association with wild-type TRIM5␣ rh , the percentage represents the fraction of the TRIM5␣ rh variant coprecipitated with wild-type TRIM5␣ rh relative to the amount of wild-type TRIM5␣ rh coprecipitated with itself. For self-association, the percentage represents the fraction of the TRIM5␣ rh variant coprecipitated with itself relative to the coprecipitation of wild-type TRIM5␣ rh with itself. ‫,ء‬ A high background was observed for the TRIM5␣ rh variant in the control sample without a TRIM5␣ target protein. The reported values may be less reliable as a result of this background.
e Binding to the HIV-1 capsid complexes was determined for each TRIM5␣ rh variant as described in Materials and Methods. Binding is expressed as the amount of the TRIM5␣ rh variant bound to HIV-1 capsid complexes divided by the amount of bound wild-type TRIM5␣ rh at a similar input level. Experiments were repeated at least three times. Note that, because the binding ratios are calculated at input levels at which some binding of the mutant TRIM5␣ rh protein to the HIV-1 capsid complexes can be detected, these ratios overestimate the relative capsid-binding affinities of the mutant proteins.
f The localization of each TRIM5␣ rh variant was determined as described in Materials and Methods. For each TRIM5␣ rh variant, cytoplasmic bodies were counted for five independent cells and compared to the number in cells expressing wild-type TRIM5␣ rh . "L" means fewer cytoplasmic bodies than wild-type TRIM5␣ rh ; "M" means more cytoplasmic bodies than the wild type, and "reticular" indicates a diffuse, reticular pattern of staining throughout the cytoplasm.
g The half-life of each TRIM5␣ rh variant was estimated by pulse-chase experiments. Every experiment was repeated at least two times. h ND, not determined.
cluding R121K, exhibited a conditional phenotype, restricting HIV-1 potently but exhibiting no inhibitory activity against the more weakly restricted N-MLV. Inhibition of HIV-1 reverse transcription by TRIM5␣ rh mutants. Potent HIV-1 restriction by TRIM5␣ rh occurs prior to the initiation of reverse transcription (22, 50) . To examine the ability of the TRIM5␣ rh B-box 2 mutants to block HIV-1 reverse transcription, we assayed the level of late reverse transcripts in mutant-expressing cells challenged with HIV-1-GFP. The percentage of GFP-positive cells was assessed in parallel to provide an indicator of successful infection (Fig. 5) . HIV-1 reverse transcripts were not detected in any of the cells expressing potently restricting TRIM5␣ rh B-box 2 mutants (Table 2). In contrast, in cells expressing B-box 2 mutants that did not restrict HIV-1 infection, the levels of HIV-1 reverse transcripts were similar to those in control cells not expressing TRIM5␣ rh (Table 2 ). Intermediate levels of reverse transcripts were found in most cells expressing TRIM5␣ rh mutants with modest HIV-1-restricting ability (Table 2) . Thus, for this panel of TRIM5␣ rh B-box 2 mutants, the levels of HIV-1 late reverse transcripts were lowest when the degree of restriction was most potent.
Effect of TRIM5␣ B-box 2 changes on HIV-1 capsid binding. Based on early, qualitative assays measuring the binding of TRIM5␣ mutants to HIV-1 capsid complexes, an effector function was proposed for the TRIM5␣ B-box 2 domain (10). Subsequently, when more quantitative capsid-binding assays were utilized, the effects of B-box 2 changes on capsid binding were recognized (32, 33) . Because the expression of some TRIM5␣ B-box 2 mutants is elevated compared to that of the wild-type protein (9), the input levels of TRIM5␣ variants must be adjusted to compare capsid-binding abilities accurately. We tested the hypothesis that the major function of the TRIM5␣ B-box 2 domain in retrovirus restriction is to increase the avidity of capsid binding. To this end, the ability of the panel of TRIM5␣ rh B-box 2 mutants to bind HIV-1 CA-NC complexes assembled in vitro was assessed. The level of each TRIM5␣ rh variant in the cell lysate was first measured, and each lysate was diluted with control cell lysates so that comparable levels of TRIM5␣ proteins were present in each input sample. The adjusted cell lysates containing the TRIM5␣ rh variants were then serially diluted and incubated with assembled HIV-1 CA-NC complexes. The mixtures were layered on a 70% sucrose cushion and centrifuged. The amount of TRIM5␣ rh protein that cosedimented with the HIV-1 CA-NC complexes was measured. Comparison of the input and bound TRIM5␣ rh levels for each mutant with those of the wild-type TRIM5␣ rh protein allowed an estimation of the relative capsid-binding affinity of the mutants (Fig. 6 ). The relative capsid-binding ability of each mutant was calculated at the lowest input concentration of the mutant protein that yielded a detectable amount of capsid binding, thus allowing a comparison among the mutants (Fig. 7A and Table 2 ). A strong correlation (r s ϭ 0.8421, P Ͻ 0.001) between binding to HIV-1 capsid complexes and HIV-1 restriction was observed for the panel of TRIM5␣ rh variants (Fig. 7B) . These results support the hypothesis that the enhancement of capsid-binding avidity represents a major contribution of the TRIM5␣ B-box 2 domain to retroviral restriction. Some of the B-box 2 mutants were expressed at higher steady-state levels than the wild-type TRIM5␣ rh protein (see Fig. S1 in the supplemental material). Although this variable is compensated for by adjusting the input levels of TRIM5␣ rh in the capsid-binding assay, varying expression levels could influence the assessment of HIV-1 restriction potency. Thus, we reanalyzed the data in Fig. 7B , separating the TRIM5␣ rh mutants into those that were highly expressed and those expressed at wild-type TRIM5␣ rh levels. The strength of the correlation was not improved by taking expression level into consideration (data not shown). Thus, TRIM5␣ rh overexpression only minimally affects HIV-1 restriction potency in this context.
Higher-order association of TRIM5␣ rh B-box 2 mutants. The B-box 2 domain has been shown to be important for the ability of TRIM5␣ dimers to associate in higher-order complexes (32) . To test the ability of the B-box 2 mutants to form higher-order complexes with the wild-type TRIM5␣ rh proteins, cell lysates containing FLAG-tagged wild-type TRIM5␣ rh and HA-tagged mutant TRIM5␣ rh proteins were mixed. After precipitation with an anti-FLAG antibody, the precipitates were Western blotted with antibodies directed against the FLAG and HA epitope tags. The wild-type TRIM5␣ rh -HA protein was efficiently coprecipitated by the anti-FLAG antibody (Fig.  8) , which is consistent with the ability of wild-type TRIM5␣ rh to self-associate in higher-order complexes. Of the TRIM5␣ rh mutants tested, only E120D was able to associate efficiently with wild-type TRIM5␣ rh ( Fig. 8 and Table 2 ). Apparently, the ability of TRIM5␣ rh to form higher-order hetero-oligomers with the wild-type TRIM5␣ rh protein is very sensitive to changes in different surface residues of the B-box 2 domain.
We examined the ability of a subset of TRIM5␣ rh mutants to self-associate into higher-order homo-oligomers ( Fig. 8D and see Fig. S4 in the supplemental material). TRIM5␣ rh mutants that exhibited efficient ability to form higher-order homooligomers restricted retrovirus infection with modest or high efficiency (Table 2) . Conversely, most of the weakly restricting TRIM5␣ mutants either did not self-associate into higherorder homo-oligomers or did so weakly. Thus, there is a significant correlation between homologous higher-order self-association of the TRIM5␣ rh variants and HIV-1-restricting ability (r s ϭ 0.862, P Ͻ 0.001) (Fig. 8E ). This observation is consistent with a model in which homologous higher-order self-association contributes to the HIV-1-restricting ability of TRIM5␣.
Cellular localization of TRIM5␣ rh B-box 2 mutants. Changes in the B-box 2 domain can change the cytoplasmic staining of the overexpressed TRIM5␣ rh protein from cytoplasmic bodies to a diffuse, reticular pattern (10) . Although a few of the B-box 2 mutants localized in well-defined cytoplasmic bodies, most of the mutants exhibited reticular staining patterns (see Fig. S5 in the supplemental material and Table 2 ). These results support previous studies that suggested that cytoplasmic body formation is not necessary for HIV-1 restriction by TRIM5␣ rh (10, 40, 49) .
DISCUSSION
We report here the structure of the TRIM5␣ B-box 2 domain, which reveals its unusual surface properties. We utilize this information to investigate which of the many reported functions of this domain relate to retroviral restriction. The TRIM5␣ B-box 2 ␤␤␣ fold is similar to that of other B-box 2 and RING-like domains. One notable feature is the surface exposure of hydrophobic residues, which are organized into two clusters, cluster 1 and cluster 2. We provide evidence that the B-box 2 domain contributes to the self-association of TRIM5␣ proteins. A stronger, zinc-mediated interaction contributed to the formation of dimers between isolated TRIM5␣ B-box 2 domains. Since the TRIM5␣ B-box 2 domain is not required for dimerization (20) and free zinc ion concentrations in the cytoplasm are low, this zinc-mediated interaction is unlikely to contribute to the association of the subunits in the TRIM5␣ dimer. All of the TRIM5␣ rh B-box 2 mutants studied herein efficiently dimerized. We identified a second, weaker interaction between the B-box 2 domains involving residues near or within cluster 1. Cluster 1 is likely exposed on the surface of the TRIM5␣ dimer, since it apparently contributes to the higher-order self-association of TRIM5␣ proteins. Alteration of W117, L118 and R121 within or near Cluster 1 resulted in TRIM5␣ rh proteins that dimerized, but could not further associate to form higher-order oligomers. Higher-order self-association of the panel of B-box 2 mutants correlated with the ability of TRIM5␣ rh to restrict HIV-1 infection. The for- mation of short-range, higher-order TRIM5␣ arrays might contribute to capsid-binding avidity (Fig. 9) . If the long-range geometry of these TRIM5␣ arrays is incompatible with that of the retroviral capsid, higher-order self-association could promote the dissolution of the viral capsid during the restriction process (9, 41, 51) . Specific changes in or near cluster 1 were shown to decrease the ability of TRIM5␣ rh to bind HIV-1 capsid-like complexes. The TRIM5␣ B-box 2 mutants exhibited a wide range of HIV-1-restricting abilities, affording us the opportunity to test the hypothesis that the major contribution of the B-box 2 domain to TRIM5␣ restriction function is mediated through capsid binding. The strong correlation that we observed between capsid-binding ability and HIV-1 restriction potency supports this hypothesis. Notably, we did not identify any B-box 2 mutants that bound the HIV-1 capsid complexes efficiently but failed to restrict HIV-1 infection; in other words, no candidate for a B-box 2 mutant defective in an "effector" function was apparent in this sizable mutant panel. Collectively, more than 80% of the TRIM5␣ B-box 2 domain surface has been altered (10, 33) , increasing the likelihood that the major functions of this domain have already been uncovered.
Coprecipitation assays were used to assess the ability of TRIM5␣ rh mutant dimers to associate with wild-type TRIM5␣ rh dimers (higher-order heterologous association) or with themselves (higher-order homologous association). The higher-order homologous association of TRIM5␣ rh mutants correlated with HIV-1-restricting activity better than heterologous association. This is expected, because in the cells tested for restriction activity, only mutant TRIM5␣ rh proteins were present. Some of the cluster 1 mutants formed higher-order homologous associations better than heterologous associations, indicating that the introduced changes were self-compatible but disruptive of interactions with the wild-type TRIM5␣ rh protein. This observation supports the importance of the B-box 2 surface proximal to cluster 1 in mediating the intermolecular contacts that stabilize the higher-order self-association of TRIM5␣ dimers.
The hydrophobic cluster 1 surface of the TRIM5␣ rh B-box 2 domain is dominated by the indole ring of W117 (W115 in human TRIM5). W117, along with L118 (L116 in human TRIM5), appears to contribute significantly to the higher-order self-association, capsid-binding avidity and HIV-1-restricting ability of TRIM5␣ rh . In addition, a basic residue, preferably an arginine residue, flanking this hydrophobic patch contributes to these functions; an arginine at the equivalent position of human TRIM5␣ has previously been shown to contribute to N-MLV restriction (10) . Some flexibility with respect to the position of this arginine residue appears to be tolerated in TRIM5␣ rh , with arginine at positions 102 or 120 able to compensate for the alteration of R121. The W117, L118, and R121 residues are all conserved in TRIM6 and TRIM34, whose B-box 2 domains can functionally substitute for those of TRIM5 (31) . These residues diverge in more distant TRIM proteins such as TRIM21, for example; the FIG. 8. Higher-order self-association of TRIM5␣ rh B-box 2 mutants. 293T cells were transfected with plasmids expressing the indicated wild-type or mutant TRIM5␣ rh proteins with a FLAG or an HA epitope tag. Cells expressing wild-type and mutant TRIM5␣ rh proteins were lysed 48 h after transfection. (A to D) The cell lysates were mixed, and the indicated mixtures were used for immunoprecipitation by an antibody directed against the FLAG epitope, as described in Materials and Methods. Elution of the immunocomplexes was performed with a FLAG tripeptide and analyzed by Western blotting with anti-HA and anti-FLAG antibodies. WB, Western blot; IP, immunoprecipitation. (E) The higher-order self-association and HIV-1-restricting ability, determined as described in the Table 2 footnotes and in Materials and Methods, of each TRIM5␣ rh variant were compared. The means of the values for higher-order self-association within each restriction group are indicated by horizontal bars. The Spearman rank correlation coefficient, r s , is 0.862, with a 95% confidence interval of 0.665 to 1.0 (two-sided P value of Ͻ0.001).
FIG. 9.
Model for the role of the TRIM5␣ B-box 2 domain in HIV-1 restriction. The TRIM5␣ rh dimer is depicted, with the B-box 2 domains (magenta) and B30.2(SPRY) domains (blue) highlighted. Interactions involving the cluster 1 region of the B-box 2 domain increase the avidity of TRIM5␣ rh for the retroviral capsid, promoting the aggregation of the TRIM5␣ rh protein on the capsid surface. (31) . Although TRIM6 and TRIM34 exhibit at best marginal ability to restrict retrovirus infection (30, 60) , higher-order self-association might contribute to other functions of these proteins. In this respect, it is notable that the dimeric contacts in the crystallized MuRF1 (TRIM63) B-box domain correspond to the cluster 1 surface of TRIM5 (37) . Thus, many TRIM proteins may utilize the corresponding surface of the B-box domain to modulate protein-protein interactions, including self-association. The levels of HIV-1 reverse transcripts detected in the cells expressing the TRIM5␣ rh mutants after HIV-1 challenge were lowest when infection was potently restricted. Conversely, in cells expressing the most restriction-defective TRIM5␣ rh proteins, the levels of reverse transcripts were comparable to those in control cells lacking TRIM5␣ rh . In cells expressing TRIM5␣ rh mutants with intermediate levels of restriction potency, a wide range of reverse transcript levels were observed following HIV-1 challenge. These results suggest that TRIM5␣ rh restriction of HIV-1 occurs early in the infection process, precluding reverse transcription when potent and allowing various degrees of reverse transcription when less potent.
Several TRIM5␣ rh B-box 2 did not form cytoplasmic bodies but still exhibited fairly potent restriction of HIV-1 infection. This observation is consistent with previous studies that suggested that cytoplasmic body formation by TRIM5␣ is not required for retroviral restriction (40, 49) . Our data do not rule out the possibility that the B-box 2-mediated higher-order selfassociation of TRIM5␣ is required for cytoplasmic body formation; however, higher-order self-association appears not to be sufficient for cytoplasmic body formation.
As previously observed (10) , some changes in the B-box 2 domain can increase the longevity of the relatively short-lived TRIM5␣ protein. Our data confirm that rapid turnover is not required for the HIV-1-restricting activity of TRIM5␣; no correlation between the half-lives and retrovirus-inhibiting abilities of the TRIM5␣ rh B-box 2 mutants was apparent. Our data also indicate that cytoplasmic body formation is not necessary for the rapid turnover of TRIM5␣.
The importance of B-box 2-mediated higher-order self-association and capsid-binding avidity to retroviral restriction should motivate efforts to understand the TRIM5␣ and capsid structures that contribute to these processes. Such understanding may suggest new interventional approaches to HIV-1 infection.
